Unjha Formulations Ltd
Incorporated in 1991, Unjha Formulations Ltd manufactures and sells Isabgol (Psyllium) Ayurvedic formulations.
- Market Cap ₹ 12.8 Cr.
- Current Price ₹ 28.5
- High / Low ₹ 39.0 / 14.8
- Stock P/E 16.0
- Book Value ₹ 7.41
- Dividend Yield 0.00 %
- ROCE 19.3 %
- ROE 10.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 23.0 days to 14.6 days
Cons
- Promoter holding is low: 36.9%
- Company has a low return on equity of 11.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.92 | 6.56 | 8.84 | 10.36 | 12.23 | 11.30 | 11.28 | 10.59 | 9.96 | 14.16 | 13.15 | 18.50 | 17.71 | |
4.75 | 6.39 | 8.65 | 10.00 | 11.86 | 10.96 | 10.98 | 10.34 | 9.83 | 13.84 | 12.71 | 17.93 | 16.63 | |
Operating Profit | 0.17 | 0.17 | 0.19 | 0.36 | 0.37 | 0.34 | 0.30 | 0.25 | 0.13 | 0.32 | 0.44 | 0.57 | 1.08 |
OPM % | 3.46% | 2.59% | 2.15% | 3.47% | 3.03% | 3.01% | 2.66% | 2.36% | 1.31% | 2.26% | 3.35% | 3.08% | 6.10% |
0.00 | 0.02 | 0.09 | 0.08 | 0.11 | 0.04 | 0.10 | 0.26 | 0.22 | 0.19 | 0.03 | 0.01 | 0.03 | |
Interest | 0.01 | 0.00 | 0.01 | 0.10 | 0.10 | 0.02 | 0.01 | 0.12 | 0.17 | 0.13 | 0.06 | 0.05 | 0.05 |
Depreciation | 0.07 | 0.07 | 0.09 | 0.08 | 0.09 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Profit before tax | 0.09 | 0.12 | 0.18 | 0.26 | 0.29 | 0.26 | 0.30 | 0.31 | 0.10 | 0.30 | 0.33 | 0.45 | 0.98 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 15.15% | 40.00% | |
0.09 | 0.12 | 0.17 | 0.26 | 0.30 | 0.26 | 0.30 | 0.31 | 0.10 | 0.25 | 0.28 | 0.28 | 0.80 | |
EPS in Rs | 0.20 | 0.27 | 0.38 | 0.58 | 0.67 | 0.58 | 0.67 | 0.69 | 0.22 | 0.56 | 0.62 | 0.62 | 1.78 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 23% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | -1% |
3 Years: | 41% |
TTM: | 420% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 27% |
3 Years: | 41% |
1 Year: | 67% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 12% |
3 Years: | 12% |
Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 |
Reserves | -4.37 | -4.26 | -4.09 | -3.83 | -3.54 | -3.27 | -2.97 | -2.67 | -2.56 | -2.31 | -2.03 | -1.75 | -1.16 |
0.00 | 0.00 | 0.40 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
2.61 | 3.54 | 2.51 | 2.28 | 2.79 | 2.75 | 2.15 | 1.90 | 1.61 | 1.28 | 0.96 | 2.20 | 2.10 | |
Total Liabilities | 2.72 | 3.76 | 3.30 | 2.93 | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 3.41 | 4.93 | 5.42 |
1.03 | 1.10 | 1.09 | 1.03 | 1.22 | 1.16 | 1.12 | 1.14 | 1.12 | 1.07 | 1.10 | 1.12 | 1.15 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
1.69 | 2.66 | 2.21 | 1.90 | 2.56 | 2.80 | 2.54 | 2.57 | 2.41 | 2.38 | 2.31 | 3.81 | 4.27 | |
Total Assets | 2.72 | 3.76 | 3.30 | 2.93 | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 3.41 | 4.93 | 5.42 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.49 | 0.53 | -0.70 | 0.41 | 0.39 | 0.14 | -0.12 | 0.39 | -0.70 | 0.28 | -0.26 | 1.03 | |
-0.02 | -0.13 | -0.09 | -0.02 | -0.28 | 0.06 | 0.04 | -0.10 | -0.06 | -0.02 | -0.10 | -0.11 | |
-0.27 | -0.02 | 0.40 | -0.40 | 0.05 | -0.05 | 0.23 | 0.00 | 0.00 | 0.00 | -0.06 | -0.05 | |
Net Cash Flow | 0.20 | 0.38 | -0.38 | -0.01 | 0.15 | 0.15 | 0.16 | 0.29 | -0.77 | 0.25 | -0.42 | 0.86 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 49.71 | 50.63 | 28.08 | 28.54 | 19.40 | 25.19 | 43.36 | 39.64 | 35.91 | 18.04 | 29.14 | 31.76 |
Inventory Days | 39.21 | 50.22 | 35.62 | 22.76 | 40.83 | 39.40 | 22.92 | 21.37 | 55.60 | 34.08 | 38.92 | 29.56 |
Days Payable | 243.64 | 250.41 | 122.48 | 94.35 | 98.20 | 106.22 | 87.50 | 82.79 | 77.35 | 39.81 | 32.10 | 47.85 |
Cash Conversion Cycle | -154.73 | -149.55 | -58.78 | -43.06 | -37.97 | -41.63 | -21.22 | -21.79 | 14.16 | 12.31 | 35.97 | 13.47 |
Working Capital Days | -100.89 | -95.14 | -30.14 | -28.19 | -24.17 | -21.96 | -8.41 | -9.31 | 22.72 | 17.27 | 37.19 | 14.60 |
ROCE % | 50.00% | 72.73% | 37.62% | 50.00% | 47.56% | 25.45% | 22.79% | 25.90% | 14.48% | 21.03% | 16.88% | 19.31% |
Documents
Announcements
-
Publish Un- Audited Financial Results For The Second Quarter& Half Year Ended As On 30.09.2024
12 Nov - Published un-audited financial results for Q2 2024.
-
Disclosure Of Related Party Transaction For The Half Year Ended 30.09.2024 Company Code : 531762
8 Nov - Disclosure of related party transactions for H1 2024.
-
Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September,2024 And Out Come Of Board Meeting Held On 8Th, November ,2024.
8 Nov - Approval of un-audited financial results for Q2 2024.
-
Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September,2024 And Out Come Of Board Meeting Held On 8Th, November ,2024.
8 Nov - Approval of un-audited financial results for Q2 2024.
-
Board Meeting Intimation for Board Meeting - Date: 08.11.2024( Un-Audited Financial Results For The Quarter And Half Year Ended On 30.09.2024)
16 Oct - Board meeting scheduled for Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Profile:[1]
Company is G.M.P. certified for manufacturing & exporting of Isabgol (Psyllium) Ayurvedic formulations products. Company's parent company M/S Urvesh Ltd. is a 100% EOU
which is also engaged in export of
Isabgol Husk & Isabgol Powder.